Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker AVTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 12,394 | $16.33 | $202.4K Sale | Form 4 ↗ |
| Sep 10, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 10,185 | $17.62 | $179.5K Sale | Form 4 ↗ |
| Aug 28, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 679 | $20.00 | $13.6K Sale | Form 4 ↗ |
| Aug 18, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 31,031 | $20.05 | $622.2K Sale | Form 4 ↗ |
| Aug 17, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 1,000 | $20.00 | $20.0K Sale | Form 4 ↗ |
| Aug 17, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 3,749 | $19.94 | $74.8K Sale | Form 4 ↗ |
| Aug 17, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 37,945 | $19.85 | $753.2K Sale | Form 4 ↗ |
| Aug 11, 2026 | Jennifer Riley Chief Strategy Officer | AVTX Avalo Therapeutics, Inc. | Sale | 2,655 | $19.59 | $52.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 679 | $20.00 | $13.6K Sale | Form 4 ↗ |
| Jul 27, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 1,000 | $20.00 | $20.0K Sale | Form 4 ↗ |
| Jun 30, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 4,654 | $20.00 | $93.1K Sale | Form 4 ↗ |
| Jun 23, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 1,450 | $18.00 | $26.1K Sale | Form 4 ↗ |
| May 28, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 679 | $16.00 | $10.9K Sale | Form 4 ↗ |
| May 15, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 3,000 | $18.76 | $56.3K Sale | Form 4 ↗ |
| May 7, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 18,606 | $24.12 | $448.8K Sale | Form 4 ↗ |
| May 6, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 10,058 | $22.88 | $230.1K Sale | Form 4 ↗ |
| May 6, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 19,015 | $22.41 | $426.1K Sale | Form 4 ↗ |
| May 6, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 44,944 | $21.20 | $952.8K Sale | Form 4 ↗ |
| May 6, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 5,000 | $19.65 | $98.3K Sale | Form 4 ↗ |
| May 6, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 27,538 | $18.03 | $496.5K Sale | Form 4 ↗ |
| May 6, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 8,900 | $22.57 | $200.9K Sale | Form 4 ↗ |
| May 6, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 9,219 | $21.37 | $197.0K Sale | Form 4 ↗ |
| May 6, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 2,700 | $20.76 | $56.1K Sale | Form 4 ↗ |
| May 6, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 12,347 | $19.28 | $238.1K Sale | Form 4 ↗ |
| May 6, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 13,834 | $18.55 | $256.6K Sale | Form 4 ↗ |
| May 6, 2026 | Mitchell Chan Director | AVTX Avalo Therapeutics, Inc. | Sale | 3,167 | $22.88 | $72.5K Sale | Form 4 ↗ |
| May 6, 2026 | Paul Varki Chief Legal Officer | AVTX Avalo Therapeutics, Inc. | Sale | 400 | $23.71 | $9,484 Sale | Form 4 ↗ |
| May 6, 2026 | Paul Varki Chief Legal Officer | AVTX Avalo Therapeutics, Inc. | Sale | 9,253 | $22.70 | $210.0K Sale | Form 4 ↗ |
| May 6, 2026 | Paul Varki Chief Legal Officer | AVTX Avalo Therapeutics, Inc. | Sale | 22,839 | $21.22 | $484.6K Sale | Form 4 ↗ |
| May 6, 2026 | Paul Varki Chief Legal Officer | AVTX Avalo Therapeutics, Inc. | Sale | 5,196 | $19.78 | $102.8K Sale | Form 4 ↗ |
| May 6, 2026 | Paul Varki Chief Legal Officer | AVTX Avalo Therapeutics, Inc. | Sale | 37,375 | $18.91 | $706.8K Sale | Form 4 ↗ |
| May 5, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 1,679 | $16.00 | $26.9K Sale | Form 4 ↗ |
| Apr 30, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 8,457 | $13.23 | $111.9K Sale | Form 4 ↗ |
| Apr 29, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 8,458 | $13.09 | $110.7K Sale | Form 4 ↗ |
| Apr 6, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 3,970 | $18.01 | $71.5K Sale | Form 4 ↗ |
| Apr 2, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 1,780 | $17.57 | $31.3K Sale | Form 4 ↗ |
| Apr 2, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 6,200 | $17.02 | $105.5K Sale | Form 4 ↗ |
| Apr 1, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 679 | $16.00 | $10.9K Sale | Form 4 ↗ |
| Apr 1, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 7,479 | $16.83 | $125.9K Sale | Form 4 ↗ |
| Apr 1, 2026 | Christopher Ryan Sullivan Chief Financial Officer | AVTX Avalo Therapeutics, Inc. | Sale | 500 | $15.86 | $7,930 Sale | Form 4 ↗ |
| Mar 16, 2026 | Doyle Mittie Chief Medical Officer | AVTX Avalo Therapeutics, Inc. | Sale | 25,492 | $16.15 | $411.7K Sale | Form 4 ↗ |
| Nov 14, 2025 | Jonathan Goldman Director | AVTX Avalo Therapeutics, Inc. | Sale | 8,200 | $14.35 | $117.7K Sale | Form 4 ↗ |
| Nov 14, 2025 | Jonathan Goldman Director | AVTX Avalo Therapeutics, Inc. | Sale | 3,167 | $14.30 | $45.3K Sale | Form 4 ↗ |
| Nov 13, 2024 | June Sherie Almenoff Director | AVTX Avalo Therapeutics, Inc. | Buy | 500 | $13.00 | $6,500 Buy | Form 4 ↗ |
| Nov 12, 2024 | June Sherie Almenoff Director | AVTX Avalo Therapeutics, Inc. | Buy | 500 | $12.50 | $6,250 Buy | Form 4 ↗ |
45 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances